Fat jabs like Ozempic really are life-saving, slashing risk of death by a third, striking new data shows By John Ely Deputy Health Editor For Mailonline Published: 08:57 BST, 30 August 2024 | Updated: 09:02 BST, 30 August 2024 e-mail View comments Semaglutide, the ingredient in jabs like Ozempic and its fat-busting cousin Wegovy, can reduce the risk of heart failure events and cardiovascular death by nearly a third research suggests. Australian and international researchers analysed health data from patients with people with diabetes taking the jab during one of its previous clinical trials. They found those taking semaglutide in the experiment could have up to 27 per cent reduced risk of heart failure and a 29 per cent reduced risk of death.
The authors say this points to how the drug may be working to benefit people with obesity-related heart failure. The results are the latest to find semaglutide could have benefits to heart health outcomes. Researchers found those taking semaglutide in the experiment could have up to 27 per cent reduced risk of heart failure and a 29 per cent reduced risk of death.
It comes after UK drug chiefs approved the use of semaglutide, to prevent heart attacks and strokes in patents who are overweight earlier this year . That decision comes after scientists hailed the results of a trial which, earlier this year, showed patients on the medications slashed their chance of suffering these health problems by up to a fifth and called for their wider ap.